City of Hope Unveils AI and Cancer Breakthroughs at AACR
LOS ANGELES, April 16, 2026 City of Hope announced that its scientists will present groundbreaking research findings on cancer...
Most Recent
Advertisement
Aligos-Amoytop $445M HBV Licensing Deal Expands Access
SOUTH SAN FRANCISCO, Calif., April 16, 2026 Aligos Therapeutics has entered into an exclusive licensing agreement with Xiamen Amoytop...
Alkermes Reports Strong Phase 2 Data for Narcolepsy Drug
DUBLIN, April 16, 2026 Alkermes plc has announced new data from its Vibrance-1 Phase 2 clinical study of alixorexton,...
Janux Therapeutics Doses First Patient in JANX014 Study
SAN DIEGO, USA, April 16, 2026 Janux Therapeutics, Inc. has announced a key clinical milestone with the first participant...
Mapi Pharma GA Depot Shows Strong MS Progression Control
NESS ZIONA, Israel, April 16, 2026 Mapi Pharma Ltd. has announced new clinical findings demonstrating that its Glatiramer Acetate...
AIM ImmunoTech Advances Ampligen Phase 3 Cancer Trial
OCALA, Fla., April 16, 2026 AIM ImmunoTech Inc. has announced significant progress in its oncology pipeline, entering a pivotal...
Khondrion Doses First Patient in Phase 3 KHENERFIN Study
NIJMEGEN, The Netherlands, April 16, 2026 Khondrion has announced a significant clinical milestone with the first patient dosed in...
MAIA Activates U.S. Site for Phase 2 Lung Cancer Trial
CHICAGO, April 16, 2026 MAIA Biotechnology, Inc. has announced the activation of its first U.S. clinical site for the...
PharmaTher Peptide Policy Boosts Microneedle Strategy
TORONTO, ON, April 16, 2026 PharmaTher Holdings Ltd. has announced its strong support for proposed U.S. regulatory reclassification of...
Neurelis Shows Strong Seizure Control Data for VALTOCO at AAN
SAN DIEGO, Calif., April 16, 2026 Neurelis, Inc. has announced new clinical and real-world analyses demonstrating the effectiveness of...
Advertisement
